Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem
Chỉ hiển thị Multimedia

Quadruple regimen shows promise as first-line treatment for extrapulmonary NEC
12 Nov 2026
bởiStephen Padilla
First-line treatment with surufatinib combined with serplulimab and etoposide/cisplatin (EP) regimen exhibits antitumour activity with manageable safety in patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma (NEC), reports a study presented at ESMO Congress 2026.
12 Nov 2026

Combined biomarkers assessment predicts ASCVD risk
10 Nov 2026
bởiStephen Padilla
A single combined assessment of low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) (Lp[a]), and high-sensitivity C-reactive protein (hsCRP) detects individuals at increased long-term risk of atherosclerotic cardiovascular disease (ASCVD) via independent pathways, according to a study.
10 Nov 2026






